CareDx Inc. (NASDAQ: CDNA) announced it will divest its Lab Products business to EuroBio Scientific for $170 million in cash, according to a company statement.

The transaction, approved by both companies' boards of directors, involves CareDx's in vitro diagnostic PCR kits for rapid deceased donor HLA typing, NGS-based kits for transplant recipient HLA typing, and NGS-based monitoring assays for solid organ and stem cell transplant recipients outside North America.

Under the agreement, CareDx will provide transition services to EuroBio Scientific for at least six months at the buyer's expense. EuroBio Scientific will grant CareDx exclusive perpetual rights to distribute post-transplant monitoring IVD tests in North America, including AlloSeq cfDNA.

"This divestiture allows us to strategically focus on our core Testing Services and Patient and Digital Solutions, where our solutions-selling strategy is working," said John Hanna, CareDx's president and CEO.

The transaction requires Swedish regulatory review and is expected to close by the end of CareDx's third quarter 2026.

CareDx also reported preliminary first quarter 2026 results, showing revenue of approximately $118 million, representing 39% year-over-year growth. Testing service volume reached approximately 54,900, up 17% year-over-year, while testing service revenue grew 48% to approximately $91 million. Patient and Digital Solutions revenue increased 33% year-over-year to approximately $16 million.

The company reported cash, cash equivalents, and marketable securities of approximately $198 million as of March 31, 2026. Lab Products revenue declined 4% year-over-year to approximately $10 million.

CareDx plans to use proceeds for investments supporting its long-term growth strategy and potential returns to shareholders. The company will provide additional guidance during its first quarter 2026 earnings call scheduled for April 28, 2026.